<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ebm.bmj.com">
<title>Evidence-Based Medicine current issue</title>
<link>http://ebm.bmj.com</link>
<description>Evidence-Based Medicine RSS feed -- current issue</description>
<prism:coverDisplayDate>Apr  1 2012 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Evidence-Based Medicine</prism:publicationName>
<prism:issn>1356-5524</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/e2?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/37?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/38?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/39?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/40?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/41?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/42?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/44?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/45?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/46?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/47?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/49?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/50?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/51?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/53?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/54?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/55?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/57?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/58?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/60?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/61?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/62?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/64?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/65?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/66?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/17/2/68?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif">
<title>Evidence-Based Medicine</title>
<url>http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif</url>
<link>http://ebm.bmj.com</link>
</image>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/e2?rss=1">
<title><![CDATA[Purpose and procedure]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/e2?rss=1</link>
<description><![CDATA[ <p>The general purpose of <I>Evidence-Based Medicine</I> is to select from the health-related literature<cross-ref type="fn" refid="FN1">*</cross-ref> those articles reporting important advances in internal medicine, general and family practice, surgery, psychiatry, paediatrics, and obstetrics and gynaecology, and whose results are most likely to be both true and useful. These articles are described, critiqued and commented on by clinical experts. The specific purposes of <I>Evidence-Based Medicine</I> are:<l type="tab"><li><p> to identify, using predefined criteria, the best original and review articles on the cause, course, diagnosis, prevention, treatment, quality of care, or economics of disorders in the foregoing fields</p> </li><li> <p> to provide a description and expert commentary on the context of each article, its methods, and the clinical applications that its findings warrant</p> </li><li> <p> to disseminate the summaries in a timely fashion</p> </li></l></p> <p>The BMJ Publishing Group publishes <I>Evidence-Based Medicine</I>.</p> <sec id="s1"><st>Criteria for selection and review of articles</st> <p>All articles in a...]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.17.02.e2</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.17.02.e2</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[Purpose and procedure]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Electronic page</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>e2</prism:startingPage>
<prism:endingPage>e2</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/37?rss=1">
<title><![CDATA[Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/37?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Sickle cell anaemia (SCA) is a disorder of haemoglobin polymerisation that results in vaso-occlusion and haemolytic anaemia, culminating in organ injury and early mortality. Elevated fetal haemoglobin has been associated with a less severe phenotype leading to an interest in hydroxycarbamide (also known as hydroxyurea) use. The MSH study<cross-ref type="bib" refid="R1">1</cross-ref> demonstrated that hydroxycarbamide in adults with severe sickle cell disease reduced painful events, hospitalisations, acute chest syndrome and the number of blood transfusions. The HUG&ndash;KIDS study,<cross-ref type="bib" refid="R2">2</cross-ref> a phase I/II study, demonstrated safety and haematologic responses to hydroxycarbamide therapy in children 5&ndash;15 years of age. The HUSOFT study<cross-ref type="bib" refid="R3">3</cross-ref> was conducted in infants and very young children for 2 years with similar end points and favourable results. Two adult trials document the benefits of hydroxycarbamide in reducing mortality in SCA.<cross-ref type="bib" refid="R4">4</cross-ref> <cross-ref type="bib" refid="R5">5</cross-ref> The BABY HUG study was designed to answer whether...]]></description>
<dc:creator><![CDATA[Manwani, D.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100104</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100104</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Haematology (incl blood transfusion), Immunology (including allergy), Drugs: CNS (not psychiatric), Pain (neurology), Chemotherapy, Radiology, Clinical diagnostic tests, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>37</prism:startingPage>
<prism:endingPage>38</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/38?rss=1">
<title><![CDATA[Randomised trial of radical prostatectomy versus watchful waiting finds reduced risk for death but uncertainty still reigns]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/38?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Data comparing surgery versus watchful waiting for prostate cancer are important, and the results are also relevant when evaluating whether and when screening for prostate cancer is effective.<cross-ref type="bib" refid="R1">1</cross-ref> Thus, deciding whether such study results are valid, and how well they generalise, is a prominent challenge in men's health.</p> </sec> <sec id="s2"><st>Methods</st> <p>This randomised trial seeks to determine whether mortality from prostate cancer is lower after radical prostatectomy than with primary expectant management. As an ongoing project for more than 20 years, prior major reports appeared in 2002,<cross-ref type="bib" refid="R2">2</cross-ref> 2005<cross-ref type="bib" refid="R3">3</cross-ref> and 2008.<cross-ref type="bib" refid="R4">4</cross-ref> The current report extends follow-up by 3 years and focuses on low-risk prostate cancer (Gleason histological score &lt;7, prostate-specific antigen level &lt;10 ng/ml) and younger men (&lt;65 years of age).</p> </sec> <sec id="s3"><st>Findings</st> <p>In summary, 695 men with localised and well-differentiated or moderately differentiated prostate cancer (mean age 65...]]></description>
<dc:creator><![CDATA[Concato, J., Guarino, P.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100101</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100101</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Editor's choice, Screening (oncology), Prostate, Screening (epidemiology), Ethics, Legal and forensic medicine, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Randomised trial of radical prostatectomy versus watchful waiting finds reduced risk for death but uncertainty still reigns]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>38</prism:startingPage>
<prism:endingPage>39</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/39?rss=1">
<title><![CDATA[Systematic review of observational studies finds increased risk of fracture among older adults taking a proton pump inhibitor]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/39?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Proton pump inhibitors (PPIs) were initially considered to be potentially beneficial for bone as they were perceived to be able to inhibit acidic degradation by osteoclasts and thus have antiresorptive potential.<cross-ref type="bib" refid="R1">1</cross-ref> However, this has been shown not to be the case, as the original studies were based on compounds differing from those used clinically.<cross-ref type="bib" refid="R1">1</cross-ref> Studies of bone density have failed to show any major changes in bone density with PPIs.<cross-ref type="bib" refid="R2">2</cross-ref> Short-term studies have failed to show an effect on calcium absorption by PPIs.<cross-ref type="bib" refid="R3">3</cross-ref></p> <p>The present study examines whether a relationship exists between the use of PPIs and histamine-2-receptor antagonists (H2RAs) and adverse effects on the skeleton. The question raised is important from an epidemiological point of view as antacid drugs are widely prescribed and available over-the-counter in some locales.</p> </sec> <sec id="s2"><st>Methods</st> <p>Yu and colleagues applied standard meta-analytic techniques...]]></description>
<dc:creator><![CDATA[Vestergaard, P.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100114</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100114</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: gastrointestinal system, Musculoskeletal syndromes, Osteoporosis, Injury]]></dc:subject>
<dc:title><![CDATA[Systematic review of observational studies finds increased risk of fracture among older adults taking a proton pump inhibitor]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>39</prism:startingPage>
<prism:endingPage>40</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/40?rss=1">
<title><![CDATA[Oxygen may reduce dyspnoea in people with COPD who have mild or no hypoxaemia]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/40?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Although supplemental oxygen (SupplO<SUB>2</SUB>) has been shown to prolong survival in chronic obstructive pulmonary disease (COPD) patients with severe hypoxaemia (ie, PaO<SUB>2</SUB>&lt;55 mm Hg or PaO<SUB>2</SUB> 55&ndash;59 mm Hg with cor pulmonale or polycythaemia), benefits in non-hypoxaemic COPD patients are less clear. Prescribing SupplO<SUB>2</SUB> for such patients is highly variable, and it is common and very costly. As such, there is a strong rationale to clarify the indications.<cross-ref type="bib" refid="R1">1</cross-ref> This meta-analysis evaluates the evidence regarding the benefits of SupplO<SUB>2</SUB> to relieve dyspnoea and enhance exercise performance and quality of life (QOL) in COPD patients whose baseline resting oxygenation is not substantially impaired.</p> </sec> <sec id="s2"><st>Methods</st> <p>The article follows the standard Cochrane review approach, that is, considers all (and only) randomised controlled trials, irrespective of blinding (ie, of inhaling oxygen vs medical air) in this case; specifies the intervention (ie, oxygen or medical air as administered through...]]></description>
<dc:creator><![CDATA[Stoller, J. K.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100127</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100127</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology)]]></dc:subject>
<dc:title><![CDATA[Oxygen may reduce dyspnoea in people with COPD who have mild or no hypoxaemia]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>40</prism:startingPage>
<prism:endingPage>41</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/41?rss=1">
<title><![CDATA[The administration of corticosteroids to 34-36-week pregnant women at risk of imminent delivery does not reduce the risk of respiratory disorders in the newborn]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/41?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>A single course of antenatal corticosteroids (ACS) is an unusual example of an intervention which leads to a cost savings and an improved health outcome for infants born before 34-week gestational age (GA).<cross-ref type="bib" refid="R1">1</cross-ref> However, the evidence with regards to its effectiveness in late preterm infants (those born between 34 and before 36 6/7 weeks) is unknown.</p> </sec> <sec id="s2"><st>Methods</st> <p>A single-centre, double-blind, randomised controlled trial of a single course of antenatal corticosteroids versus placebo in women at high risk of preterm birth between 34 and 36 6/7 weeks GA. Between April 2008 and June 2010, 320 women were randomised, 163 to ACS and 157 to placebo, at a large tertiary hospital in Recife, Brazil. Women randomised to the ACS group received two doses of 12 mg of &beta;-methasone intramuscularly every 24 h, and those randomised to placebo received a placebo of similar appearance. Women were...]]></description>
<dc:creator><![CDATA[Murphy, K. E.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100150</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100150</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), Epidemiologic studies, Pregnancy, Sports and exercise medicine, Diabetes]]></dc:subject>
<dc:title><![CDATA[The administration of corticosteroids to 34-36-week pregnant women at risk of imminent delivery does not reduce the risk of respiratory disorders in the newborn]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>41</prism:startingPage>
<prism:endingPage>42</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/42?rss=1">
<title><![CDATA[Cardiac resynchronisation therapy reduces mortality in patients with heart failure but questions remain]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/42?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Cardiac resynchronisation therapy (CRT) is now a well-established therapy for certain subgroups of patients with heart failure, with a large body of evidence demonstrating improvement in symptoms and beneficial changes in cardiac structure and function. American and European guidelines support its use in patients with New York Heart Association (NYHA) class III and IV heart failure, prolonged QRS duration and left ventricular ejection fraction &lt;35%. The COMPANION trial<cross-ref type="bib" refid="R1">1</cross-ref> demonstrated an all-cause mortality benefit of CRT when combined with implantable cardioverter defibrillator (ICD) therapy in this subgroup, and, subsequently, the CARE-HF trial<cross-ref type="bib" refid="R2">2</cross-ref> established a mortality benefit attributable to CRT alone when compared with optimal medical therapy (OMT). More recently, the REVERSE<cross-ref type="bib" refid="R3">3</cross-ref> and MADIT-CRT<cross-ref type="bib" refid="R4">4</cross-ref> trials in patients with less severe, NYHA class I and II heart failure symptoms showed improved cardiac function and reduction in heart failure hospitalisation in patients treated...]]></description>
<dc:creator><![CDATA[Luckie, M., Khattar, R. S.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm-2011-100074</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm-2011-100074</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system]]></dc:subject>
<dc:title><![CDATA[Cardiac resynchronisation therapy reduces mortality in patients with heart failure but questions remain]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>42</prism:startingPage>
<prism:endingPage>43</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/44?rss=1">
<title><![CDATA[In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting {beta} agonists provided equivalent short-term asthma quality of life but were associated with more medication switches]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/44?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Asthma is a common condition for which there are robust evidence-based guidelines.<cross-ref type="bib" refid="R1">1</cross-ref> Such guidelines are by definition based on the gold standard of randomised controlled trials (RCTs) which often have restrictive, inclusion and exclusion criteria, such that patients enrolled are not representative of patients seen in real world settings. Pragmatic trial designs have been suggested as a method of overcoming some of these limitations.<cross-ref type="bib" refid="R2">2</cross-ref></p> </sec> <sec id="s2"><st>Methods</st> <p>In two parallel, multicentre open-labelled pragmatic trials, Price and colleagues evaluated the effectiveness of inhaled corticosteroids (ICS) versus leukotriene receptor antagonists (LTRAs) as initial asthma therapy (in trial 1) and the addition of an LTRA or a long-acting &beta; agonist (LABA), by random allocation, for participants who remained uncontrolled after 12 weeks of ICS (in trail 2). Participants with physician-diagnosed asthma were recruited from 53 primary care practices in the UK. The study was not funded...]]></description>
<dc:creator><![CDATA[FitzGerald, J. M.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100140</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100140</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), General practice / family medicine, Immunology (including allergy), Asthma, Drugs: respiratory system, Guidelines]]></dc:subject>
<dc:title><![CDATA[In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting {beta} agonists provided equivalent short-term asthma quality of life but were associated with more medication switches]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>44</prism:startingPage>
<prism:endingPage>45</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/45?rss=1">
<title><![CDATA[Early (at 34-35 weeks) external cephalic version reduced the risk of non-cephalic (breech) presentation at birth but has no effect on risk of caesarean section]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/45?rss=1</link>
<description><![CDATA[
<p>Commentary on: 
<bib><other-ref><firstauthor><snm>Hutton</snm> <fnm>EK</fnm></firstauthor>, Hannah ME, Ross SJ, <I>et al</I>.. The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. <I><title>BJOG</title></I> <date>2011;</date><b><volume-nr>118</volume-nr></b>:<first-page>564</first-page>&ndash;77.</other-ref></bib>
</p>
]]></description>
<dc:creator><![CDATA[Tan, P. C.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100125</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100125</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Pregnancy]]></dc:subject>
<dc:title><![CDATA[Early (at 34-35 weeks) external cephalic version reduced the risk of non-cephalic (breech) presentation at birth but has no effect on risk of caesarean section]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>45</prism:startingPage>
<prism:endingPage>46</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/46?rss=1">
<title><![CDATA[Warming local anaesthetic prior to injection reduces injection pain]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/46?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>For many patients, the worst part of a procedure, such as a tooth extraction or a carpal tunnel decompression, is likely to be the initial pain following the insertion of a needle and the injection of local anaesthetic. There are reports that warming local anaesthetics before injection can reduce pain, but the effectiveness of this approach has not been accurately determined. The purpose of this systematic review was to examine whether the strategy of warming local anaesthetic prior to injection reduces self-report of pain.</p> </sec> <sec id="s2"><st>Methods</st> <p>The authors used an accepted search strategy and analysis of randomised or pseudo-randomised studies that compared warmed local anaesthetics with those not warmed before injection. Some of the studies involved volunteers while others involved subjects receiving injections for different indications such as surgery in the head and neck region, closure of lacerations, venipuncture, carpal tunnel decompression or dental anaesthesia in...]]></description>
<dc:creator><![CDATA[Leaper, D.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100165</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100165</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Drugs: CNS (not psychiatric), Pain (neurology), Drugs: musculoskeletal and joint diseases, Dentistry and oral medicine]]></dc:subject>
<dc:title><![CDATA[Warming local anaesthetic prior to injection reduces injection pain]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>46</prism:startingPage>
<prism:endingPage>47</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/47?rss=1">
<title><![CDATA[Ovarian cancer screening has no effect on disease-specific mortality]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/47?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Ovarian cancer is the leading cause of death from gynaecological malignancies in developed countries. The majority of the deaths occur in women with invasive epithelial ovarian cancer, most of whom present with advanced disease. This has led to a huge effort in early detection. Buys and colleagues report on the first adequately powered trial to assess the impact of screening on mortality.</p> </sec> <sec id="s2"><st>Methods</st> <p>Between November 1993 and December 2001, the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial randomised 34 253 women aged 55&ndash;74 to ovarian cancer screening (OCS) and 34 304 to control. Women in the screen arm were offered annual serum CA125 interpreted using a cut-off of 35 U/ml and transvaginal ultrasound for 4 years. Those still eligible in 1999 had two further screens of CA125 alone. The evaluation and management of positive screening tests was at the discretion of the participants'...]]></description>
<dc:creator><![CDATA[Menon, U.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100163</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100163</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Screening (oncology), Radiology, Clinical diagnostic tests, Radiology (diagnostics), Prostate, Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Ovarian cancer screening has no effect on disease-specific mortality]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>47</prism:startingPage>
<prism:endingPage>48</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/49?rss=1">
<title><![CDATA[A 2-year early childhood psychosocial stimulation programme improves cognitive outcomes and decreases violent behaviour at 22 years for children with growth retardation]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/49?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>The aim of this study was to evaluate the long-term effects of early childhood stimulation and/or nutritional supplementation on growth-retarded children in Jamaica, a developing country.</p> </sec> <sec id="s2"><st>Methods</st> <p>Children (N=129) between 9 and 24 months with growth retardation were randomly allocated to four groups for a 2-year trial: (1) control, (2) nutritional supplementation (1 kg milk-based formula per week), (3) psychosocial stimulation (weekly play sessions to improve mother&ndash;child interaction) or (4), nutritional supplementation and psychosocial stimulation. The long-term effects of the intervention were assessed at 7, 11, 17 and 22 years.</p> </sec> <sec id="s3"><st>Findings</st> <p>Walker and colleagues reported educational, cognitive, social and health outcomes at 22 years for 105 participants. No significant effects were observed for those who received only nutritional supplementation. However, compared with other participants, those who received the psychosocial stimulation programme had higher IQ (p=0.004), higher educational attainment (p=0.033), better general knowledge (p=0.005),...]]></description>
<dc:creator><![CDATA[Tremblay, R. E.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100158</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100158</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), Childhood nutrition, Child and adolescent psychiatry, Personality disorders, Sports and exercise medicine]]></dc:subject>
<dc:title><![CDATA[A 2-year early childhood psychosocial stimulation programme improves cognitive outcomes and decreases violent behaviour at 22 years for children with growth retardation]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>49</prism:startingPage>
<prism:endingPage>50</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/50?rss=1">
<title><![CDATA[Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/50?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Screening for breast, colorectal and prostate cancer is recommended to begin at an earlier age for individuals at increased risk because of their family history, compared with individuals at average risk. Some clinical guidelines have also suggested using more sensitive screening modalities for individuals with family histories of cancer, such as MRI for breast cancer screening. Since screening recommendations are different based on family history characteristics, it is important to know how family cancer history might change over time. Most family cancer history information is collected from patients on their initial visit and no evidence exists to help guide the clinician on how often family history information should be updated.</p> </sec> <sec id="s2"><st>Methods</st> <p>This study reviewed family cancer history information reported from individuals with either a personal or family history of cancer who had enrolled in the Cancer Genetics Network (CGN). Family cancer history information was assessed...]]></description>
<dc:creator><![CDATA[Murff, H. J.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100190</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100190</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Screening (oncology), Surgical diagnostic tests, Prostate, Screening (epidemiology), Guidelines, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>50</prism:startingPage>
<prism:endingPage>51</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/51?rss=1">
<title><![CDATA[Management of patients hospitalised with community-acquired pneumonia: dexamethasone reduces length of stay by 1 day]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/51?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Pneumonia develops when pathogens invading the sterile lower respiratory tract activate the innate immune response to generate local and systemic inflammation.<cross-ref type="bib" refid="R1">1</cross-ref> The host's inability to fully downregulate systemic inflammation is the dominant pathogenetic process contributing to acute and long-term morbidity and mortality. In the last decade, we have recognised that, for pneumonia, (1) acute mortality has not improved since the introduction of antibiotics, (2) the heart is a major target organ with more cardiovascular events (particularly for those with atherosclerosis), (3) biological resolution lags weeks behind clinical resolution and (4) most patients discharged from the hospital have subclinical low-grade systemic inflammation and substantial excess mortality for years.<cross-ref type="bib" refid="R1">1</cross-ref> On the basis of 1-year mortality, pneumonia is the third leading cause of death in the USA and a public health priority.</p> <p>The two components of an infection are pathogens and inflammation. Current treatment is directed...]]></description>
<dc:creator><![CDATA[Meduri, G. U., Confalonieri, M.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100154</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100154</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Pneumonia (infectious disease), Pneumonia (respiratory medicine), Diabetes]]></dc:subject>
<dc:title><![CDATA[Management of patients hospitalised with community-acquired pneumonia: dexamethasone reduces length of stay by 1 day]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>51</prism:startingPage>
<prism:endingPage>52</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/53?rss=1">
<title><![CDATA[In patients hospitalised with acute heart failure, nesiritide, compared with placebo, is not associated with improvements in dyspnoea or 30-day rehospitalisation or mortality]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/53?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>In 2001 the FDA approved nesiritide for the treatment of acutely decompensated heart failure. As a potent intravenous vasodilator, nesiritide reduces cardiac filling pressures leading to symptomatic improvement in patients with acutely decompensated heart failure.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4">4</cross-ref> However, this drug remains heavily debated even years after its approval, mainly because of a lack of substantial long-term safety data.<cross-ref type="bib" refid="R5">5</cross-ref> In light of this evidence, the manufacturer gathered a panel of experts in 2005 in order to address this issue. One of the recommendations of the panel was to conduct a clinical trial on drug safety. The objective of this commentary is the discussion of the ASCEND-HF trial and its results published in the New England Journal of Medicine.</p> </sec> <sec id="s2"><st>Methods</st> <p>The randomised placebo-controlled trial was conducted in Europe and the US. Patients were eligible to participate if they had...]]></description>
<dc:creator><![CDATA[Salzberg, S. P.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100176</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100176</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: cardiovascular system, Hypertension, Interventional cardiology]]></dc:subject>
<dc:title><![CDATA[In patients hospitalised with acute heart failure, nesiritide, compared with placebo, is not associated with improvements in dyspnoea or 30-day rehospitalisation or mortality]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>53</prism:startingPage>
<prism:endingPage>54</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/54?rss=1">
<title><![CDATA[In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/54?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Treatment of venous thromboembolism has evolved considerably over the last twenty years. The use of subcutaneous low molecular weight heparin without a requirement for monitoring has lessened the burden of treatment and opened the door for outpatient therapy.<cross-ref type="bib" refid="R1">1</cross-ref> This is a well-accepted practise for patients with deep vein thrombosis (DVT), but concern has remained for similar treatment of pulmonary embolism.</p> <p>Some of the reluctance to treat as an outpatient is emotional, given that many patients with DVT already have an asymptomatic pulmonary embolism.<cross-ref type="bib" refid="R2">2</cross-ref> There clearly is legitimate concern as well, given the high risk of complications with pulmonary embolism, including higher death and in some studies, higher risk of recurrence.<cross-ref type="bib" refid="R3">3</cross-ref> Our group and others in Canada and Europe have been treating patients with a pulmonary embolism on an outpatient basis using loosely defined criteria: eligible patients must have no hypoxia, hypotension,...]]></description>
<dc:creator><![CDATA[Wells, P. S.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100191</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100191</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Palliative care, Medical management, Epidemiologic studies, Pain (neurology), Venous thromboembolism, Pulmonary embolism]]></dc:subject>
<dc:title><![CDATA[In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>54</prism:startingPage>
<prism:endingPage>55</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/55?rss=1">
<title><![CDATA[Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/55?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Evidence suggests that the health benefits of statin therapy may extend beyond its cholesterol-lowering properties, potentially including favourable effects on systemic inflammation, endothelial function and oxidative stress &ndash; important mechanisms involved in the aetiology of cardiometabolic diseases.<cross-ref type="bib" refid="R1">1</cross-ref> However, contrary to such a putative benefit, meta-analyses of randomised trials have recently suggested that statin use is associated with elevated diabetes risk compared with placebo.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> In this meta-analysis, Preiss and colleagues reported that intensive-dose statin therapy is associated with a 12% increase in risk of incident type 2 diabetes compared with moderate dose statin treatment, thus proposing a dose-response relationship for the statin-diabetes association.</p> </sec> <sec id="s2"><st>Methods</st> <p>The authors identified statin trials using MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (January 1996 through March 2011). Inclusion criteria for the trials included comparison of intensive-dose versus moderate-dose statin therapy, sample...]]></description>
<dc:creator><![CDATA[Rajpathak, S. N.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100198</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100198</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Drugs: cardiovascular system, Diet, Ischaemic heart disease, Diabetes]]></dc:subject>
<dc:title><![CDATA[Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>55</prism:startingPage>
<prism:endingPage>56</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/57?rss=1">
<title><![CDATA[Sensitivity of pulse oximetry for detection of critical congenital heart defects in newborn infants higher than that of antenatal ultrasound with few false positives]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/57?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Albert Einstein defined insanity as "doing the same thing over and over again and expecting different results". Such is the state of detecting congenital heart defects (CHD) in newborns. For years, clinicians have been taught that a careful physical examination of the newborn can detect CHD while witnessing cases of failed detection of newborns with critical CHD (CCHD). Despite these failures, we never critically addressed our strategy. The recent study by Ewer <I>et al</I> on the accuracy of pulse oximetry as a screening tool for CHD adds more credence to a new strategy to improve detection.</p> </sec> <sec id="s2"><st>Methods</st> <p>This prospective study was performed in six obstetric units in the West Midlands, UK. The main aim was evaluation of sensitivity and specificity of pulse oximetry for detection of CCHD (causing death or requiring invasive intervention before 28 days). Pulse oximetry was measured in the upper and lower...]]></description>
<dc:creator><![CDATA[Martin, G. R., Bradshaw, E. A.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100290</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100290</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Genetics, Radiology, Renal medicine, Clinical diagnostic tests, Radiology (diagnostics), Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Sensitivity of pulse oximetry for detection of critical congenital heart defects in newborn infants higher than that of antenatal ultrasound with few false positives]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Diagnostics</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>57</prism:startingPage>
<prism:endingPage>58</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/58?rss=1">
<title><![CDATA[Hammering the point home: serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/58?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>A rapid and accurate, yet inexpensive test to diagnose active pulmonary tuberculosis (TB) would increase detection of cases, and might diagnose patients at an earlier stage of disease reducing morbidity and mortality, as well as transmission. Currently the most widely used rapid test is acid fast bacilli (AFB) smear microscopy. AFB smears are inexpensive, and can provide results within hours. However, they are insensitive, detecting approximately half of all pulmonary TB cases, albeit those who are sicker and more contagious with more advanced disease. TB cultures are considered the gold standard for diagnosis but are more expensive and complex, and only provide results after weeks to months. The potential alternatives are serologic tests that use ELISA techniques to detect a humoral response (ie, detect antibodies) to TB. Many different tests have been developed, tested and marketed, and in many countries are widely used to diagnose TB. However,...]]></description>
<dc:creator><![CDATA[Menzies, D.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100291</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100291</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Hammering the point home: serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Diagnosis</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>58</prism:startingPage>
<prism:endingPage>59</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/60?rss=1">
<title><![CDATA[Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retention]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/60?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Chronic obstructive pulmonary disease (COPD) affects 1 in 10 individuals more than 40 years of age.<cross-ref type="bib" refid="R1">1</cross-ref> Many of these patients use inhaled anticholinergic (IAC) medications, often as a first-line therapy.<cross-ref type="bib" refid="R2">2</cross-ref> Although IACs are generally poorly absorbed from the gastrointestinal and respiratory tracts, approximately 10&ndash;15% of the drug make it into the systemic circulation.<cross-ref type="bib" refid="R3">3</cross-ref> Cholinergic receptors are expressed in prostatic tissue, and their stimulation may cause urinary retention.<cross-ref type="bib" refid="R4">4</cross-ref> However, the risk of acute urinary retention (AUR) related to IAC use in the older COPD population is not known.</p> </sec> <sec id="s2"><st>Methods</st> <p>This was a population-based nested case-control study from Ontario, Canada, in which the risk of AUR was compared between users and non-users of IACs in a group of older patients (defined as 66 years of age or older) with COPD (defined as those with a previous hospitalisation or office...]]></description>
<dc:creator><![CDATA[Kyskan, R., Sin, D. D.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100143</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100143</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Palliative care, Clinical trials (epidemiology), Epidemiologic studies, Renal medicine, Prostate]]></dc:subject>
<dc:title><![CDATA[Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retention]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Prognosis</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>60</prism:startingPage>
<prism:endingPage>61</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/61?rss=1">
<title><![CDATA[Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/61?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Non-steroidal anti-inflammatory drugs (NSAIDs) have been implicated in causing negative cardiovascular outcomes, particularly in coronary artery disease (CAD) patients who have had a prior myocardial infarction (MI). In fact, as Schjerning Olsen and colleagues point out, current guidelines give the rather nebulous recommendation that duration of NSAID therapy should be as short as possible in CAD patients.<cross-ref type="bib" refid="R1">1</cross-ref></p> <p>The study by Schjerning Olsen and colleagues seeks to characterise the association between NSAID treatment duration and risk of cardiovascular disease. Although selective cyclooxygenase 2 inhibitors (COX-2) such as rofecoxib and valdecoxib have received notoriety and media attention,<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> this observational analysis aims to establish a link between treatment duration with non-selective NSAIDs (diclofenac, ibuprofen, naproxen) and MI and death.</p> </sec> <sec id="s2"><st>Methods</st> <p>Death and/or recurrent MI associated with NSAID use in patients admitted from 1997 to 2006 with first-time MI are studied in...]]></description>
<dc:creator><![CDATA[Chakrabarti, A. K., Gibson, C. M.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100132</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100132</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: cardiovascular system, Pain (neurology), Ischaemic heart disease, Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases]]></dc:subject>
<dc:title><![CDATA[Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Prognosis</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>61</prism:startingPage>
<prism:endingPage>62</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/62?rss=1">
<title><![CDATA[Modelling study of prognostic indicators for patients with locally advanced or metastatic cancer identifies variables that predict short-term survival in palliative care]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/62?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>A key function of palliative care is to provide accurate information about prognosis with a level of specificity that patients and their families want. However, a large evidence base indicates that healthcare providers are often not able to make an accurate prognostic assessment and that prognostic predictions tend to be overly optimistic.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Even palliative care providers, whose predictions should be the most accurate, tend to overestimate survival.<cross-ref type="bib" refid="R3">3</cross-ref></p> <p>This optimism bias is not homogeneous. In fact, providers working in specialised settings such as the intensive care unit may be able to make more accurate predictions.<cross-ref type="bib" refid="R4">4</cross-ref> <cross-ref type="bib" refid="R5">5</cross-ref> Nevertheless, most healthcare providers imagine that their patients will live longer than they actually will. Therefore, there is an urgent need for valid, reliable tools that can facilitate accurate prognostication and which can promote more informed decision-making.</p> </sec> <sec id="s2"><st>Methods</st> <p>Gwilliam...]]></description>
<dc:creator><![CDATA[Casarett, D.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100303</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100303</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Palliative care, Oesophagus, Epidemiologic studies, Immunology (including allergy)]]></dc:subject>
<dc:title><![CDATA[Modelling study of prognostic indicators for patients with locally advanced or metastatic cancer identifies variables that predict short-term survival in palliative care]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Prognosis</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>62</prism:startingPage>
<prism:endingPage>63</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/64?rss=1">
<title><![CDATA[Enhancing the Framingham Risk Score for coronary heart disease by adding information on working hours]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/64?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>The Framingham Risk Score is a widely used prediction model for the assessment of risk for coronary heart disease (CHD), which contains traditional risk factors (age, sex, blood pressure, cholesterol, diabetes and smoking status).<cross-ref type="bib" refid="R1">1</cross-ref> However, other more non-traditional (psychosocial) factors have also emerged as risks for CHD. The purpose of the study by Kivim&auml;ki <I>et al</I> was to determine whether the addition of working hours to the Framingham Score improves the risk prediction of this model.</p> </sec> <sec id="s2"><st>Methods</st> <p>The authors used a prospective cohort of British civil servants enrolled in the Whitehall II study, which examines health behaviour, work environment and socioeconomic status as they pertain to clinical disease.<cross-ref type="bib" refid="R2">2</cross-ref> Baseline data were collected during phase III of the parent study (1991&ndash;1993) and included daily working hours and traditional risk factors. Individuals who worked part time, those with known CHD and those with...]]></description>
<dc:creator><![CDATA[Graham, M. M.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm-2011-100087</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm-2011-100087</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Hypertension, Ischaemic heart disease, Health education, Smoking]]></dc:subject>
<dc:title><![CDATA[Enhancing the Framingham Risk Score for coronary heart disease by adding information on working hours]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Aetiology</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>64</prism:startingPage>
<prism:endingPage>64</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/65?rss=1">
<title><![CDATA[Modifiable risk factors for stillbirth in high-income countries include overweight and obesity, maternal age and smoking]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/65?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>Almost 3 million babies are born with no signs of life worldwide every year.<cross-ref type="bib" refid="R1">1</cross-ref> To contribute to the increasing awareness of stillbirth prevention in the global health agenda, <I>The Lancet</I> has recently published the &lsquo;Stillbirth Series&rsquo;.<cross-ref type="bib" refid="R2">2</cross-ref> This set of original articles and commentaries is an excellent summary of what is currently known about this problem, mainly from a public health perspective, but is also useful for clinical care.</p> <p>Although 98% of stillbirths occur in low- and middle-income countries, they also occur in high-income countries in approximately 1 out of every 300 births, and many are preventable.<cross-ref type="bib" refid="R2">2</cross-ref> In one of the series articles, Flenady and colleagues have conducted a systematic review addressing the risk factors for stillbirths in high-income countries.</p> </sec> <sec id="s2"><st>Methods</st> <p>The authors studied factors related to maternal demographics and lifestyle, medical disorders and pregnancy complications that could potentially be...]]></description>
<dc:creator><![CDATA[Althabe, F.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100109</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100109</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Epidemiologic studies, Hypertension, Obesity (nutrition), Pregnancy, Drugs misuse (including addiction), Health education, Smoking]]></dc:subject>
<dc:title><![CDATA[Modifiable risk factors for stillbirth in high-income countries include overweight and obesity, maternal age and smoking]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Aetiology</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>65</prism:startingPage>
<prism:endingPage>66</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/66?rss=1">
<title><![CDATA[Babies exposed to newer-generation antiepileptic drugs (compared with no antiepileptic drug exposure) in the first-trimester of pregnancy are not at increased risk of major birth defects]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/66?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Context</st> <p>In the last few years, more information has been published regarding birth defects associated with the use of the new generation of antiepileptic drugs (AEDs). Some recent reports from different registries have shown a lower rate of major birth defects associated with the use of new generation AEDs compared with some of the first-generation AEDs. For example, an Australian registry showed no increase in major birth defects with the use of lamotrigine in the first trimester.<cross-ref type="bib" refid="R1">1</cross-ref> But a North American registry reported a significant increase in the presence of oral clefts in infants exposed to lamotrigine during pregnancy, in contrast with a European registry which showed no association between rate of birth defects and the use of lamotrigine.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> Another study from Finland reported no increase in the rate of congenital malformations with the use of oxcarbazepine.<cross-ref type="bib" refid="R4">4</cross-ref></p> </sec> <sec...]]></description>
<dc:creator><![CDATA[Tellez-Zenteno, J. F.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100096</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100096</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epilepsy and seizures, Pregnancy, Drugs: psychiatry]]></dc:subject>
<dc:title><![CDATA[Babies exposed to newer-generation antiepileptic drugs (compared with no antiepileptic drug exposure) in the first-trimester of pregnancy are not at increased risk of major birth defects]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Aetiology</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>66</prism:startingPage>
<prism:endingPage>67</prism:endingPage>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/17/2/68?rss=1">
<title><![CDATA[Book review: systematic reviews to support evidence-based medicine. Second edition: from expert to novice and back again]]></title>
<link>http://ebm.bmj.com/cgi/content/short/17/2/68?rss=1</link>
<description><![CDATA[ <p>I ran into systematic reviews (SRs) in 1989. Dodging the draft, I had just spent 4 months on the middle ear reflex of Wistar rats, hoping to, some day, prevent human hearing damage. Instead of unraveling nature, I discovered that I was attracted more to applied science. At the Maastricht University Epidemiology department, I started reading randomised trials on acupuncture. My boss had convinced the Department of Health that reading the existing evidence was a better investment than spending at least twice the amount on the next trial that carefully ignored its predecessors' lessons. We were busy carrying out, what we called &lsquo;criteria-based meta-analyses&rsquo; (CBMA), which we then (mis)judged superior to taking weighted averages (statistical pooling). These CBMAs boiled down to vote-counts for subgroups that differed on quality. Our basic (or biased?) expectation was that as quality goes up, the proportion of &lsquo;positive&rsquo; studies should go down. But in...]]></description>
<dc:creator><![CDATA[ter Riet, G.]]></dc:creator>
<dc:date>2012-03-24T01:41:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100441</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100441</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Book review: systematic reviews to support evidence-based medicine. Second edition: from expert to novice and back again]]></dc:title>
<prism:publicationDate>2012-04-01</prism:publicationDate>
<prism:section>Resource review</prism:section>
<prism:volume>17</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>68</prism:startingPage>
<prism:endingPage>68</prism:endingPage>
</item>
</rdf:RDF>
